Email this article 
Efek Pemberian N-Acetylcysteine Oral terhadap Kadar hsCRP Serum pada Continuous Ambulatory Peritoneal Dialysis
Abstract
Inflamasi dan stres oksidatif merupakan faktor risiko kardiovaskuler pada pasien chronic kidney disease (CKD).N-asetilsistein (NAS) mengandung thiol sebagai antioksidan yang memiliki aktivitas antiinflamasi dan memperlihatkan penurunan angka kejadian kardiovaskuler pada pasien hemodialisis. Penelitian ini bertujuan menentukan efek NAS oral (2 x 600 mg/hari) terhadap kadar petanda inflamasi pada pasien Continuous Ambulatory Peritoneal Dialysis (CAPD). Perlakuan diberikan selama 8 minggu pada 32 pasien (80% laki-laki, usia 42±7 tahun) yang menjalani regular CAPD. Sebelum perlakuan pasien dibagi menjadi dua kelompok masing-masing 16 pasien.Sitokin proinflamasi (high-sensitivity Creactive protein/hsCRP) diukur sebelum dan sesudah perlakuan dengan NAS. Hasil penelitian menunjukkan bahwa pemberian NAS, secara bermakna menurunkan kadar hsCRP (-1,50±1,32 vs 0,56±1,25 pg/mL, p<0,001) dibandingkan kelompok kontrol. Disimpulkan bahwa pemberian NAS peroral mampu menurunkan kadar hsCRP pasien CAPD.
Keywords
Full Text:
PDFReferences
Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J. 2007;28: 478–483 ;
Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005 ; 20:1048–56.
Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3:505–21.
Zachwieja J, Zaniew M, Bobkowski W, Stefaniak E, Warzywoda A, Ostalska-Nowicka D, et al. Beneficial in vitro effect of N-acetylcysteine on oxidative stress and apoptosis. Pediatr Nephrol. 2005;20:725–31.
Jourde-Chiche N, Dou L, Cerini C, DignatGeorge F, Brunet P. Vascular incompetence in dialysis patients—protein-bound uremic toxins and endothelial dysfunction. Semin Dial. 2011;24(3):327-37
Nolan C. Strategies for Improving Long-Term Survival in Patients with ESRD.J Am Soc Nephrol. 2005;16:S120–S127.
Clendenen TV, Koenig KL, Arslan AA, Lukanova A, Berrino F, Gu Y et al. Factors associated with inflammation markers, a crosssectional analysis. Cytokine. 2011 Dec; 56(3): 769-78
Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drueke T, Santangelo F, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int. 2003;64:82–91
Priya S, Vijayalakshmi P, Vivekanandan P, Karthikeyan S. Influence of N-acetylcysteine against dimethylnitrosamine induced hepatotoxicity in rats. Toxicol Ind Health. 2011 Nov; 27:914-922.
Tepel M. N-Acetylcysteine in the prevention of ototoxicity.Kidney Int. 2007;72:231–2.
Jourde-Chiche N, Dou L, Cerini C, DignatGeorge F, Brunet P. Vascular incompetence in dialysis patients—protein-bound uremic toxins and endothelial dysfunction. Semin Dial. 2011;24(3):327-37.
Brunet P, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, Dignat-George F, Jourde-Chiche N, Argiles A, Burtey S. Does uremia cause vascular dysfunction? Kidney Blood Press Res 2011;34(4):284-90
Ramirez R, Martin-Malo A, Aljama P. Inflammation and hemodiafiltration. Contrib Nephrol 2007;158:210-5.
Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloot S, Barreto FC, et al.Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2011;6: 2374–83
Cuzzocrea S, Mazzon E, Costantino G, SerrainoI, De Sarro A, Caputi AP. Effects of nacetylcysteine in a rat model of ischemia and reperfusion injury. Cardiovasc Res. 2000 ; 47(3):537-548.
Hayakawa H, Ishibashi T, Sekiguchi M. A novel mechanism for preventing mutations caused by oxidation of guanine nucleotides. EMBO. 2003; 4(5): 479-83.
Nascimento MM, Suliman ME, Silva M, Chinaglia T, Marchioro J, Hayashi SY, et al. Effect of oral n-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis Patients: a placebo-controlled study. Perit Dial Int. 2010; 30:336-42.
Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992–5.
Zachwieja J, Zaniew M, Bobkowski W, Stefaniak E, Warzywoda A, Ostalska-Nowicka D, et al. Beneficial in vitro effect of N-acetylcysteine on oxidative stress and apoptosis. Pediatr Nephrol. 2005;20:725–31.
Bridgeman MM, Marsden M, MacNee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax. 1991;46:39–42
Thaha M, Widodo, Pranawa W, Yogiantoro M, Tomino Y. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Clin Nephrol. 2008;69:24–32.
Glorieux G, Vanholder R. New uremic toxins which solutes should be removed? Contrib Nephrol. 2011;168:117-28
DOI: https://doi.org/10.18196/mmjkk.v11i2.936
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Editorial Office:
Journal Room, G1 (Biomedic) Building, Ground Floor, Faculty of Medicine and Health Science Universitas Muhammadiyah Yogyakarta,
Jalan Lingkar Selatan (Brawijaya), Tamantirto, Kasihan, Bantul, Daerah Istimewa Yogyakarta, Indonesia
Phone: +62 274 387 656 (ext: 231)
WA : +62 811-2650-303
Website: http://journal.umy.ac.id/index.php/mm
E-mail: mmjkk@umy.university
Mutiara Medika: Jurnal Kedokteran dan Kesehatan is licensed under a Creative Commons Attribution 4.0 International License. View My Stats